A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer

Author: McMeekin D.S.   Gordon A.   Fowler J.   Melemed A.   Buller R.   Burke T.   Bloss J.   Sabbatini P.  

Publisher: Elsevier

ISSN: 0090-8258

Source: Gynecologic Oncology, Vol.90, Iss.1, 2003-07, pp. : 64-69

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content